Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors
暂无分享,去创建一个
A. Bellizzi | Donghong Wang | T. O'Dorisio | M. Sue O’Dorisio | S. K. Sherman | J. Maxwell | J. Howe | Jennifer C. Carr | S. Sherman
[1] J. Strosberg. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[2] Donghong Wang,et al. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors. , 2013, Surgery.
[3] A. Bellizzi,et al. Overexpression of Membrane Proteins in Primary and Metastatic Gastrointestinal Neuroendocrine Tumors , 2013, Annals of Surgical Oncology.
[4] J. Howe,et al. Translational research in endocrine surgery. , 2013, Surgical oncology clinics of North America.
[5] K. Shah,et al. Surgery for metastatic neuroendocrine tumors with occult primaries. , 2013, The Journal of surgical research.
[6] A. Bellizzi. Assigning Site of Origin in Metastatic Neuroendocrine Neoplasms: A Clinically Significant Application of Diagnostic Immunohistochemistry , 2013, Advances in anatomic pathology.
[7] M. V. van Velthuysen,et al. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. , 2013, European journal of cancer.
[8] H. Lehnert,et al. [Diagnostics and therapy for neuroendocrine neoplasia of an unknown primary - a plea for open exploration]. , 2013, Zentralblatt fur Chirurgie.
[9] Mohid S. Khan,et al. Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches , 2013, Clinical Cancer Research.
[10] W. Harmsen,et al. Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[11] D. Hörsch,et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[12] Y. Menda,et al. The Value of Preoperative Imaging in Small Bowel Neuroendocrine Tumors , 2013, Annals of Surgical Oncology.
[13] J. Fletcher,et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. , 2012, Surgery.
[14] P. Spanheimer,et al. Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling. , 2012, Surgery.
[15] M. Falconi,et al. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases , 2012, The British journal of surgery.
[16] K. Öberg,et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Hanlin L. Wang,et al. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin , 2012, Modern Pathology.
[18] A. Ganetsky,et al. Gastroenteropancreatic Neuroendocrine Tumors: Update on Therapeutics , 2012, The Annals of pharmacotherapy.
[19] S. Dry,et al. Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier , 2012, Clinical Cancer Research.
[20] J. Mezhir,et al. Comparison of Clinicopathologic Factors in 122 Patients with Resected Pancreatic and Ileal Neuroendocrine Tumors from a Single Institution , 2012, Annals of Surgical Oncology.
[21] E. Baudin,et al. ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary , 2011, Neuroendocrinology.
[22] M. Falconi,et al. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors , 2011, Neuroendocrinology.
[23] T. Gress,et al. ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas , 2011, Neuroendocrinology.
[24] F. Eggeling,et al. Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases , 2011, Clinical & Experimental Metastasis.
[25] M. Falconi,et al. Role of Resection of the Primary Pancreatic Neuroendocrine Tumour Only in Patients with Unresectable Metastatic Liver Disease: A Systematic Review , 2011, Neuroendocrinology.
[26] Y. Bang,et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[27] M. Choti,et al. Surgical Management of Hepatic Neuroendocrine Tumor Metastasis: Results from an International Multi-Institutional Analysis , 2010, Annals of Surgical Oncology.
[28] E. Nakakura,et al. Identification of Unknown Primary Tumors in Patients With Neuroendocrine Liver Metastases , 2010, Archives of surgery.
[29] C. Schade-Brittinger,et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Manal M. Hassan,et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] G. Åkerström,et al. Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors , 2008, World Journal of Surgery.
[32] B. Diggs,et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. , 2006, Surgery.
[33] D. Nagorney,et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. , 2003, Journal of the American College of Surgeons.
[34] U. Henschke,et al. Value of preoperative , 1966 .
[35] Fynn Rw. One hundred years after. , 1959 .
[36] W. M. Barclay. Surgery , 1894, Bristol medico-chirurgical journal.
[37] S. Dry,et al. A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors , 2014, Modern Pathology.
[38] E. Bs,et al. Population-Level Analysis of Pancreatic Neuroendocrine Tumors 2 cm or Less in Size , 2013, Annals of Surgical Oncology.
[39] J. Stockman,et al. Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .
[40] V. Ambrosini,et al. Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[41] R. Jensen,et al. Gastroenteropancreatic neuroendocrine tumours. , 2008, The Lancet. Oncology.